You are here

Pilot phase II study of metronomic chemotherapy in combination with bevacizumab in patients with advanced non-squamous non-small cell lung cancer

Benjamin S. Jones, Mary S. Jerome, Deborah Miley et al.

Lung Cancer, Volume 106, April 2017, Pages 125–130

Commentary by Stefan Zimmermann

Since the term was coined in 2000 by Browder et al and Klement et al, metronomic chemotherapy has been extensively studied as an antiangiogenic cancer therapy, relying on lower doses and more frequent administration of chemotherapeutics, often in combination with “pure” antiangiogenics such as bevacizumab, with the power to reduce the toxic effects and prevent rapid vascular regrowth that can lead to tumour growth during therapy breaks in conventional schedules. Nevertheless, the optimal role for this modality in the treatment sequence, and its efficacy compared with standard of care chemotherapy, in advanced NSCLC is unknown. The present study demonstrates a longer time to progression and overall survival compared with historical controls, and provides a first hint that first-line metronomic chemotherapy might be of interest, and definitely warrants further exploration, particularly in times when first-line therapy paradigms are changing so rapidly. 

Stay informed

Subscribe to our E-Alert to keep up to date with the new items in the Resource Centre

Society partner

Made possible by an educational grant from

Please note that Lilly Oncology has no editorial control over the content of this Resource Centre. The Resource Centre and all content therein has been subjected to an independent editorial review.

A few pearls from ELCC 2017

5-8 May 2017, Geneva

by Stefan Zimmermann

A high-level forum where critical issues we face as thoracic oncologists are discussed, and cutting-edge new research is presented. 

Perspectives in Lung Cancer 2017

How I optimize treatment for my NSCLC patients with advanced and aggressive disease


Now available: Webcast on demand


 

Interactive Case Reports

Read more about recent cases from the Journal of Thoracic Oncology. Test your knowledge and answer the questions following the case to get immediate feedback.